

Patient Information				
Last Name: _____				
First Name: _____ MI: _____ Sex: <input type="checkbox"/> M <input type="checkbox"/> F				
DOB (mm/dd/yyyy): _____ SSN: _____				
Parent/Guardian (if applicable): _____ (REQUIRED if patient is <18 years old at time of sample collection)				
Address: _____ City: _____				
State: _____ Zip: _____ Phone: _____				
ICD-10 Diagnosis Code(s)				
Primary ICD-10 Code (REQUIRED)	Additional ICD-10 Code(s) (OPTIONAL)			
1	2	3	4	5
Billing Information				
BILL: <input type="checkbox"/> Insurance* <input type="checkbox"/> Laboratory <input type="checkbox"/> Patient/Self-Pay <input type="checkbox"/> Provider Account *Please provide details below <u>AND</u> attach a front/back copy of insurance card(s).				
Insurance Carrier: _____ Policy #: _____				
Provider/Account Information				
Account Name/Address: _____				
Phone: _____ Fax: _____				
Ordering Provider Selection & Signature (REQUIRED)				
Clearly select the ordering provider from list below (circle or ✓). If provider is not listed, please provide their FULL NAME AND NPI:				
Provider: _____ NPI: _____ I certify the ordered test(s) is/are reasonable and medically necessary for the diagnosis, care, and/or treatment of this patient's condition as documented in the medical record. If this patient is <18 years old at the time of testing, the parent/guardian has been informed that they will be responsible for any costs associated with testing. *Informed consent for genetic testing: I have read and understand the genetic consent requirement on page two and acknowledge I have obtained consent from my patient.				
Signature: _____				
Name: _____ Date: _____				
Sample Collection Information				
Date (mm/dd/yyyy): _____ Time: _____ <input type="checkbox"/> AM <input type="checkbox"/> PM				
Patient ID: _____ Sender Sample ID: _____				
MEDICARE ONLY - HOSPITAL STATUS WHEN SAMPLE WAS COLLECTED: <input type="checkbox"/> Hospital Inpatient <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Non-Hospital Patient				
Laboratory/Other Name/Address: _____				
Phone: _____ Fax: _____				
Results: <input type="checkbox"/> Mail <input type="checkbox"/> Fax <input type="checkbox"/> No Results to Lab				

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn's disease; IV: Intravenous; SC: Subcutaneous; TPMT: thiopurine methyltransferase; HCV: Hepatitis C; NASH: Non-alcoholic steatohepatitis

Select Test(s) To Be Performed		
— Therapeutic Drug Monitoring —		
<input type="checkbox"/> Anser® IFX (#3150) Simultaneously measures infliximab (IFX) and antibody-to-IFX (ATI) levels. Select biologic and route of administration (optional): <input type="checkbox"/> ZYMFENTRA® SC (IFX-dyyb) <input type="checkbox"/> AVSOLA® IV (IFX-axxq) <input type="checkbox"/> RENFLEXIS® IV (IFX-abda) <input type="checkbox"/> INFLECTRA® IV (IFX-dyyb) <input type="checkbox"/> REMICADE® IV (infliximab) <input type="checkbox"/> Other: _____		
<input type="checkbox"/> Anser® ADA (#3170) Simultaneously measures adalimumab (ADA) and antibody-to-ADA (ATA) levels. Select biologic (optional): <input type="checkbox"/> HUMIRA® (adalimumab) <input type="checkbox"/> Other: _____		
<input type="checkbox"/> Anser® VDZ (#3180) Simultaneously measures vedolizumab (VDZ) and antibody-to-VDZ (ATV) levels.		
<input type="checkbox"/> Anser® UST (#3190) Simultaneously measures ustekinumab (UST) and antibody-to-UST (ATU) levels. Select biologic (optional): <input type="checkbox"/> STELARA® (ustekinumab) <input type="checkbox"/> Other: _____		
<input type="checkbox"/> Anser® RZB (#3140) New Simultaneously measures risankizumab (RZB) and antibody-to-RZB (ATR) levels.		
Anser Testing - Biologic Dosing Data (optional)		
Date of Last Dose (mm/dd/yyyy)	Current Dose	Current Interval
	<input type="checkbox"/> mg <input type="checkbox"/> mg/kg	<input type="checkbox"/> days <input type="checkbox"/> weeks
<input type="checkbox"/> RiskImmune®+ (#3600) Assesses genetic predisposition to immunogenicity to anti-TNF therapy.		
<input type="checkbox"/> TPMT Genetics+ (#3300) Aids in individualized thiopurine dosing based on patient TPMT genotype.		
<input type="checkbox"/> TPMT Enzyme (#3320) Phenotyping test that aids in individualized thiopurine dosing.		
<input type="checkbox"/> Thiopurine Metabolites (#3200) Aids in optimization of thiopurine dosing to achieve clinical response.		
Current Thiopurine Dosing (optional)		
<input type="checkbox"/> 6-MP _____ mg/day	<input type="checkbox"/> AZA _____ mg/day	<input type="checkbox"/> Other _____ mg/day
— Celiac, Bile Acid Malabsorption, Liver & Lactase Non-Persistence —		
<input type="checkbox"/> Celiac PLUS+ (#6360) Includes Celiac Genetics and Celiac Serology. <input type="checkbox"/> ONLY Celiac Genetics+ (#6260) Genetic profile to aid diagnosis of celiac disease. <input type="checkbox"/> ONLY Celiac Serology (#1155) Antibody profile to aid diagnosis of celiac disease. — ONLY the following designated component(s) of Celiac Serology — <input type="checkbox"/> Anti-Human Tissue Transglutaminase IgA (tTG IgA) (#1405) <input type="checkbox"/> Anti-Endomysial IgA (EMA IgA) (#1505) <input type="checkbox"/> Total serum IgA (#1605) <input type="checkbox"/> DGP IgA (#1255) <input type="checkbox"/> DGP IgG (#1355)		
<input type="checkbox"/> 7C4 Diagnostic (#8205) Measures 7α-hydroxy-4-cholesten-3-one (7C4) to determine if bile acid malabsorption may be the underlying cause of GI symptoms.		
<input type="checkbox"/> FIBROSpect® HCV (#4000) Assessment of liver fibrosis severity for HCV patients.		
<input type="checkbox"/> FIBROSpect® NASH (#4100) Assessment of liver fibrosis severity for NASH patients.		
<input type="checkbox"/> LactoTYPE®+ (#6100) Genetic test that aids in identification of primary lactase non-persistence.		
Miscellaneous Testing		
<input type="checkbox"/> Other Prometheus Testing+: _____ +Acknowledgment of informed consent required if genetic testing is indicated above. Refer to page two or contact Client Services to confirm specimen requirements.		
— Specimen collection requirements on page 2 —		
*Acknowledgment of informed consent for genetic testing required. *Failure to provide the required data, at the time of sample collection, may result in reporting delay/cancellation.		

Specimen Collection and Handling Procedures					
Test Ordered	Turnaround Time ^a	Transport Kit and Storage Conditions	Specimen Type and Volume	Specimen Collection Tube	Specimen Stability
7C4 Diagnostic	7 days	Cold pack REQUIRED Do not freeze	1.0 mL Serum	Serum Separator Tube or Red-Top Tube	Room temp: 3 days Refrigerated: 7 days
Anser ADA, IFX, RZB, UST, VDZ	3 days	Ambient or cold pack Do not freeze	2.0 mL Serum (0.5 mL for Peds)	Serum Separator Tube or Red-Top Tube	Room temp: 14 days Refrigerated: 14 days
Celiac PLUS[†]	4 days	Ambient or cold pack Do not freeze	2.0 mL Serum AND 2.0 mL Whole Blood	Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube	Room temp: 7 days Refrigerated: 30 days
Celiac Genetics[†]	4 days	Ambient or cold pack Do not freeze	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 7 days Refrigerated: 30 days
Celiac Serology (including all components)	4 days	Ambient or cold pack Do not freeze	2.0 mL Serum (0.5 mL for peds)	Serum Separator Tube or Red-Top Tube	Room temp: 7 days Refrigerated: 30 days
Crohn's Prognostic[†]	7 days	Ambient or cold pack Do not freeze	2.0 mL Serum AND 2.0 mL Whole Blood	Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube	Room temp: 7 days Refrigerated: 7 days
FIBROSpect HCV, NASH	7 days	Ambient or cold pack Do not freeze	2.0 mL Serum (0.5 mL for peds)	Serum Separator Tube or Red-Top Tube	Room temp: 7 days Refrigerated: 30 days
IBD sgi Diagnostic^{††}	4 days	Ambient or cold pack Do not freeze	2.0 mL Serum AND 2.0 mL Whole Blood	Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube	Room temp: 7 days Refrigerated: 21 days
LactoTYPE[†]	7 days	Ambient or cold pack Do not freeze	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 7 days Refrigerated: 30 days
Monitr[®] Crohn's Disease	5-7 days	Cold pack preferred Do not freeze	2.0 mL SPUN Serum	SPUN Serum Separator Tube	Room temp: 3 days Refrigerated: 14 days
RiskImmune^{††}	4 days	Ambient or cold pack. Do not freeze	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 10 days Refrigerated: 30 days
Thiopurine Metabolites	3 days	Cold pack preferred Do not freeze	5.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 24 hours Refrigerated: 8 days
TPMT Enzyme	3 days	Cold pack preferred Do not freeze	5.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 24 hours Refrigerated: 8 days
TPMT Genetics[†]	4 days	Ambient or cold pack Do not freeze	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room temp: 10 days Refrigerated: 30 days

^aBusiness days from date of receipt.

[†]Acknowledgment of informed consent for genetic testing required.

Specimens should be labeled with 2 identifiers and date of collection. Examples of acceptable identifiers include, but are not limited to: patient name, date of birth, hospital number, requisition, accession, or unique random number. Unlabeled specimens will not be accepted for testing.

SHIPPING INSTRUCTIONS: Prometheus has an agreement with FedEx[®] for express overnight delivery within the United States and Canada. Please call FedEx at 1-800-GoFedEx (463-3339) to schedule a pickup. FedEx will pick up your specimens and ship them to Prometheus Laboratories Inc. in San Diego at no expense to you. Prometheus will provide specimen transportation kits upon request. **NOTE:** Multiple specimens may be shipped in a single transportation kit. **For more information, call Client Services at 888-423-5227, or go to [prometheuslabs.com](https://www.prometheuslabs.com).**

ACKNOWLEDGMENT OF INFORMED CONSENT FOR GENETIC TESTING

I warrant that this test was ordered and that I have obtained the appropriate prior written consent. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person) and includes the following (unless certain that the following information is not required by the state in which I practice):

1. The purpose of this test is to determine if the patient may have a variant in the gene(s) being tested, which has been found to be associated with this condition.
2. This test will only test for this specific condition and will not detect ALL possible variants within this gene, nor will it detect variants in other genes.
3. Prior to my signature of the written consent, a qualified healthcare professional discussed with the patient the genetic test ordered and described the steps involved in the test, the constraints of the procedure, and its accuracy.
4. My patient was advised by a qualified healthcare professional of the risks and benefits of genetic testing, and advised of the significance of a positive and negative result.
5. The patient understands that a positive test result is an indication that the patient may be predisposed to, or have, the condition listed.
6. The patient understands that the test may fail, that the results may be non-informative or not predictive for his/her case, and that the test may reveal information that is unrelated to their intended purpose.
7. No unauthorized test is performed on specimens.
8. NY-state specimens will be destroyed within 60 days after collection when no longer required for clinical purposes.
9. The informed consent does not authorize the use or release of any other identified medical information unrelated to this genetic test
10. The patient understood that he/she could see professional genetic counseling prior to undergoing the testing procedure, and received written information identifying a genetic counselor or medical geneticist by his/her treating provider.